肺癌根治性治愈性治疗后的监测:ASCO指南
ASCO专家小组基于2000至2019年文献(14项相关研究)制定指南,建议I-III期非小细胞肺癌和小细胞肺癌根治性治疗后每6个月影像监测2年、之后每年监测以发现新原发肺癌,胸部CT为最佳手段,不推荐FDG PET/CT、循环生物标志物用于监测,脑MRI不用于I-III期NSCLC常规监测、可用于I-III期SCLC治疗后第1年每3个月和第2年每6个月。
要点
- I-III期NSCLC和SCLC根治性治疗后每6个月影像监测2年,之后每年监测。
- 胸部CT是监测复发和新原发肺癌的最佳影像手段。
- FDG PET/CT和循环生物标志物不应用于监测策略。
诊断标准与关键数值
- 监测影像频率为每6个月1次持续2年,之后每年1次,用于检出复发和新原发肺癌。
- 胸部CT是监测的最佳影像方式。
- FDG PET/CT不应作为监测工具。
- 循环生物标志物不应作为监测复发策略。
临床应用与阅片要点
- 对临床不适合或不愿接受进一步治疗的患者,可不提供监测影像。
- 年龄不应作为排除监测影像的依据。
- I-III期NSCLC不应用脑MRI进行常规监测;I-III期SCLC根治性治疗后第1年可每3个月、第2年可每6个月进行脑MRI。
局限性
- 文献检索仅纳入2000至2019年发表的系统综述、Meta分析、随机对照试验及前瞻性和回顾性比较观察性研究,共识别14项相关研究,证据基础有限。
- 专家组成员使用现有证据和非正式共识制定推荐,非正式共识本身构成方法学局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To provide evidence-based recommendations to practicing clinicians on radiographic imaging and biomarker surveillance strategies after definitive curative-intent therapy in patients with stage I-III non-small-cell lung cancer (NSCLC) and SCLC.
METHODS: ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, radiology, primary care, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2019. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.
RESULTS: The literature search identified 14 relevant studies to inform the evidence base for this guideline.
RECOMMENDATIONS: Patients should undergo surveillance imaging for recurrence every 6 months for 2 years and then annually for detection of new primary lung cancers. Chest computed tomography imaging is the optimal imaging modality for surveillance. Fluorodeoxyglucose positron emission tomography/computed tomography imaging should not be used as a surveillance tool. Surveillance imaging may not be offered to patients who are clinically unsuitable for or unwilling to accept further treatment. Age should not preclude surveillance imaging. Circulating biomarkers should not be used as a surveillance strategy for detection of recurrence. Brain magnetic resonance imaging should not be used for routine surveillance in stage I-III NSCLC but may be used every 3 months for the first year and every 6 months for the second year in patients with stage I-III small-cell lung cancer who have undergone curative-intent treatment.
引用
- Schneider BJ, Ismaila N, Aerts J, et al. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. J Clin Oncol. 2019. PMID: 31829901. doi:10.1200/JCO.19.02748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。